Cleaving pre-fusion state sars-cov-2 spike protein
AssigneeAbClonal Science, Inc.
InventorsYang Xiang, Yan Tan
Life of this patent
Estimating the term…
Abstract
Disclosed is producing recombinant SARS-CoV-2 spike protein in a pre-fusion state, using furin knock out or knockdown mammalian cells (such as HEK293, CHO or other mammalian cells) and using them to generate antibodies and related binding agents. The antibodies/binding agents can be used in SARS-CoV-2 detection assays or in diagnosis of active or prior infection with SARS-CoV-2; in prophylaxis or as a therapeutic; or for prophylactic or therapeutic use against coronaviruses related to SARS-CoV-2.
Claims4
1-20. (canceled)
A process of generating the mature, active form of the SARS-CoV-2 S protein comprising cleaving the unmutated pre-fusion form of S protein with furin at a cleavage site between amino acid Arginine 682 and amino acid Serine 686 to yield the mature, active form of SARS Cov2 S protein containing the S1 and S2 subunits.
The process of claim 1 wherein the cleavage site is between Arginine 685 and Serine 686.
The process of claim 1 wherein the cleavage site is between Arginine 670 and Serine 671 in the extracellular domain shown in SEQ ID NO.:
- 16.
Dependencies are inferred from the claim text.